ライフサイエンスコーパス: pregnant

1 to 49 years of age (excluding those who were pregnant).

2 ipient with a technical success is >30 weeks pregnant.

3 ination, pregnant to natural breeding or not pregnant.

4 ents have delivered healthy babies and 5 are pregnant.

5 tamorphopsia in her right eye while 21 weeks pregnant.

6 o are now ageing into adulthood and becoming pregnant.

7 they are nursing, pregnant or plan to become pregnant.

8 co smoke, and ever pregnant or not currently pregnant.

9 ement in women who might subsequently become pregnant.

10 different dimensions of prenatal distress in pregnant adolescents, a population at high risk for dist

11 women were similar to those reported for non-pregnant adult patients who developed COVID-19 pneumonia

12 are substantially more sensitive than in non-pregnant adults (OR = 17.2, 95% Cr.I. 13.8-21.6), and th

13 itors rapidly suppress HIV viral load in non-pregnant adults, few published data from randomised cont

14 the vaginal microbiota and immune factors in pregnant African women who were HIV-uninfected (n = 314)

15 , and some start to quit smoking after being pregnant, although existing guidelines for pregnancy rec

16 al pertussis incidence was 5.7/100,000 among pregnant and 7.3/100,000 among non-pregnant women.

17 niversal regressive practice of exclusion of pregnant and breastfeeding women from these trials.

18 and medical use of exogenous cannabinoids by pregnant and breastfeeding women.

19 embryonic diapause, females are continuously pregnant and lactating at the same time throughout their

20 line imaging modality for palpable masses in pregnant and lactating women, but data regarding breastf

21 A similar proportion of pregnant and non-pregnant patients reported ever having

22 The median age of pregnant and non-pregnant patients was 29.0 and 33.0 yea

23 tem to describe pertussis epidemiology among pregnant and non-pregnant women of childbearing age.

24 characteristics of disease are similar among pregnant and non-pregnant women.

25 une responses, we inoculated immunocompetent pregnant and nonpregnant female C57BL/6 mice with 5 x 10

26 on to identify risk factors for mortality in pregnant and peripartum patients receiving extracorporea

27 PrEP implementation for pregnant and post-partum women lags behind implementatio

28 etween Nov 20, 2017, and June 13, 2018, 9376 pregnant and post-partum women were assessed for behavio

29 is (PrEP) based on tenofovir to HIV-negative pregnant and post-partum women with a substantial risk o

30 plies to adults 18 years or older, including pregnant and postpartum persons, and adolescents aged 12

31 ivity, 70% to 97%; specificity, 50% to 89%), pregnant and postpartum women (Edinburgh Postnatal Depre

32 erapy (ART) initiation appears frequently in pregnant and postpartum women living with human immunode

33 diagnosed with anxiety disorders, including pregnant and postpartum women.

34 pregnant or post partum, gestational age (if pregnant), and HIV risk factors in the previous 6 months

35 isolated from plasma of nonpregnant, healthy pregnant, and GDM women at 24-28 weeks of gestation.

36 h human immunodeficiency virus, who were not pregnant, and who were >=24 years.

37 of patients with known pregnancy status were pregnant at cough onset.

38 excluded if they were younger than 18 years, pregnant at the time of randomisation, or were enrolled

39 in the first or second trimester were still pregnant at the time of this report.

40 Timed-pregnant baboons (n = 6) were inoculated via vaginal dep

41 sessed in an in vivo placental model - timed-pregnant Balb/c mice at gestational day (GD) 18.5.

42 ophilus and Bifidobacterium infantis (LB) to pregnant C57/BL6J mice daily from E16 to weaning, signif

43 ers was significantly associated with SCH in pregnant Chinese women.

44 blood plasma samples (50 GDM and 50 healthy pregnant control group) were submitted Attenuated Total

45 Pregnant dams (F0 generation) were exposed to the vehicl

46 Exposure of pregnant dams to PolyI:C during early pregnancy reduced

47 significant systemic vascular alteration in pregnant dams, which likely suppresses critical blood fl

48 od was similar to that in women who were not pregnant during the corresponding epochs.

49 scular function and increase fetal growth in pregnant endothelial NO synthase knockout (eNOS(-/-) ) m

50 Pregnant female CD-1 mice were randomly assigned to one

51 example, when an intervention is applied to pregnant female rodents (genuine replicates) but the hyp

52 e body temperatures during winter, while non-pregnant females exhibited a temporary decrease in their

53 gies according to reproductive status, where pregnant females maintained stable body temperatures dur

54 ign was performed out from a database of 671 pregnant females, using six different sets of criteria f

55 ia is the most common placental pathology in pregnant females, with increased morbidity and mortality

56 especially in some population groups such as pregnant females.

57 hat are subsequently transferred into pseudo-pregnant fosters.

58 Furthermore, fecal bile acids are reduced in pregnant Fxr(-/-) mice.

59 Uteri from pregnant GEN-exposed mice were posteriorized and had red

60 ogenes caused disproportionate illness among pregnant girls and women and HIV-infected persons.

61 tion, and by 3 weeks postinoculation, 75% of pregnant guinea pigs experienced stillbirths or spontane

62 Phoenix et al. (1959) reported that treating pregnant guinea pigs with testosterone had enduring effe

63 MRI data were collected from pregnant mice after administration of b-BSA-Gd-DTPA and

64 We compared the toxicity of PFOA and GenX in pregnant mice and their developing embryo-placenta units

65 Compared with nonpregnant mice, pregnant mice exhibited higher frequencies of uterine ma

66 cted in uterine arteries (UtA) isolated from pregnant mice exposed to hypoxia or normoxia from gestat

67 We found that pregnant mice had lower frequencies of uterine Ag-experi

68 Ag-experienced CD4 T cells and ZIKV-infected pregnant mice had lower frequencies of uterine Ag-experi

69 ge response (DDR) in these cells, we exposed pregnant mice to ionizing radiation (IR) at specific ges

70 For testing, pregnant mice were administered dexamethasone (DEX), a s

71 Dhcr7(+/-) and wild-type time-pregnant mice were exposed to vehicle or 0.2 mg/kg CAR f

72 the lungs and was self-resolving, whereas in pregnant mice, virus dissemination to major maternal blo

73 ytidylic acid (poly (I:C)) was injected into pregnant mice.

74 administering a hepcidin peptide mimetic to pregnant mice.

75 study (GWAS) for self-reported glycosuria in pregnant mothers from the Avon Longitudinal Study of Par

76 hormone hepcidin is profoundly decreased in pregnant mothers, which is thought to ensure adequate ir

77 s each year, primarily in young children and pregnant mothers.

78 ples from 15 females (n = 16 cycling, n = 36 pregnant, n = 39 lactating) using 16S rRNA gene amplicon

79 ed a perinatal home-visiting intervention to pregnant Native American youth.

80 ys with HIV-positive adults who were neither pregnant nor breastfeeding.

81 spectively classified as pregnant (P) or non-pregnant (NP).

82 y trial, eligible WLHIV were ages 18-40, not pregnant or desiring pregnancy within 30 months, screene

83 socially disadvantaged women who are either pregnant or have recently become a new parent.

84 posure to secondhand tobacco smoke, and ever pregnant or not currently pregnant.

85 for CAR use, especially if they are nursing, pregnant or plan to become pregnant.

86 age, marital status, marriage type, whether pregnant or post partum, gestational age (if pregnant),

87 diagnosed with anxiety disorders, including pregnant or postpartum women, and compared clinical outc

88 arms of treatment and no treatment trials in pregnant or postpartum women.

89 fers that were retrospectively classified as pregnant (P) or non-pregnant (NP).

90 expectant fathers who registered with their pregnant partners were invited to participate in this st

91 llees (78.2% [99% CI, 77.6-78.7]); including pregnant patients (58.9% [99% CI, 47.7%-69.4%]) and pati

92 A similar proportion of pregnant and non-pregnant patients reported ever having received Tdap (31

93 Compared to non-pregnant patients, more pregnant patients reported whoop (41.9% vs. 31.3%), post

94 The median age of pregnant and non-pregnant patients was 29.0 and 33.0 years, respectively.

95 rther, because of the difficulty of studying pregnant patients, high-quality research evaluating the

96 Compared to non-pregnant patients, more pregnant patients reported whoop

97 arms of screening for bacterial vaginosis in pregnant persons at increased risk for preterm delivery.

98 against screening for bacterial vaginosis in pregnant persons not at increased risk for preterm deliv

99 This recommendation applies to pregnant persons without symptoms of bacterial vaginosis

100 It is known that pig offspring born from pregnant pigs exposed to elevated ambient temperatures d

101 Fifteen pregnant pigs were allocated to thermoneutral (TN; 20 de

102 Ten pregnant pigtail macaques received choriodecidual inocul

103 r diagnosis of pulmonary embolism in the non-pregnant population show limitations for diagnosis in pr

104 I 1.5-24], respectively) than in the general pregnant population.

105 s and hypertension become more common in the pregnant population.

106 n be used to guide PrEP adherence support in pregnant/postpartum African women.

107 simulated a systemic virus exposure in early pregnant rats (gestational day 8.5) by administering the

108 iffness of the vaginal wall decreased 82% in pregnant rats and 74% (p = 0.019) with injury relative t

109 1 were administered into the amniotic sac of pregnant rats at Embryonic Day 20 to simulate antenatal

110 Methods: Endotoxin (ETX) was administered to pregnant rats by intraamniotic injection at Embryonic Da

111 The uterus of pregnant rats was removed by cesarean section and the fe

112 The pregnant rats were injected with BrdU at embryonic day 1

113 high-risk women who are or intend to become pregnant remains an important public health issue.

114 me ZIKV genomes in experimentally inoculated pregnant rhesus macaques and their fetuses.

115 HIV-negative, non-pregnant Rwandan BV patients were randomized to four gro

116 ng insulin was elevated in mice infused with pregnant sEVs as compared to sEVs from nonpregnant and G

117 In our study of pregnant South African women with accurately dated pregn

118 rangements of the MHC II pathway among fully pregnant species were identified in both genera of the s

119 ptions are available for patients who may be pregnant, those who have specific clinical conditions, s

120 The females were later classified as pregnant to artificial insemination, pregnant to natural

121 fied as pregnant to artificial insemination, pregnant to natural breeding or not pregnant.

122 ers in Kenya who had the potential to become pregnant, to improve their contraceptive knowledge and b

123 antiviral response and hypoxia in the early pregnant uterus, containing the primordial placenta and

124 V mutations capable of augmenting fitness in pregnant vertebrates may not necessarily spread efficien

125 In pregnant wild-type mice, ZIKV I1404 increased the magnit

126 Uterine arteries from late pregnant wildtype and LOX-1 overexpressing mice were inc

127 This case report describes a pregnant woman with symptomatic coronavirus disease who

128 We enrolled pregnant women (<=20 weeks gestation) and followed them

129 id content were determined in faeces from 35 pregnant women (14 with uncomplicated pregnancies and 21

130 mpaigns in the observational studies and 397 pregnant women (399 pregnancy outcomes) purposely receiv

131 pregancy outcomes were included, of whom 496 pregnant women (500 pregnancy outcomes) received ivermec

132 uman immunodeficiency virus (HIV)-uninfected pregnant women (68 IIV3 and 77 placebo recipients) and 1

133 A total of 156 pregnant women (age 26.62 +/- 3.93 years) within the ges

134 cohort included racially/ethnically diverse pregnant women (aged 20-45 years-33% primiparous, 37% bi

135 ere lower than in the obese or normal-weight pregnant women (basal levels: 13.66 +/- 5.88 vs. 19.03 +

136 Fifteen pregnant women (mean gestational age, 37.8 weeks) walked

137 During the study period, 306 pregnant women (median age 29 years, 52.9% Hispanic or L

138 At baseline, 40% of pregnant women (median gestational age 28 weeks) require

139 All pregnant women aged >=15 years were followed-up during p

140 We enrolled 351 pregnant women and 109 controls with epilepsy.

141 d use of new drugs, prospective follow-up of pregnant women and birth surveillance studies such as Ts

142 ze seasonal influenza hospitalizations among pregnant women and can inform assessments of the public

143 n deficiency continues to pose a problem for pregnant women and fetal development, an incomplete unde

144 tic drug was changed at least once in 74% of pregnant women and in 31% of controls (odds ratio, 6.36;

145 example, the vulnerability of groups such as pregnant women and taught other lessons valuable for fut

146 United States, and thus the unique needs of pregnant women and their infants should be considered in

147 gnancy are urgently needed to better protect pregnant women and their newborns.

148 nutrition, supplemental nutrition offered to pregnant women and their offspring below the age of 6 ye

149 protein-calorie food supplements offered to pregnant women and their offspring below the age of 6 ye

150 er potential to reduce the metabolic risk in pregnant women and their offspring.

151 cosanoids longitudinally across gestation in pregnant women and to determine whether levels differed

152 Non-Hispanic Black pregnant women and women from Southern Central Valley ge

153 Pregnant women are an important at-risk population to co

154 Globally, 1.4 million pregnant women are estimated to be living with HIV/AIDS,

155 s for severe COVID-19 in adults, but data in pregnant women are limited.

156 to increase influenza vaccine coverage among pregnant women are needed, particularly in vulnerable po

157 A substantial proportion of pregnant women are prescribed opioids at doses that incr

158 ts with COVID-19 is increasing, many exclude pregnant women as participants or do not address pregnan

159 ussis (Tdap) vaccine was recommended for all pregnant women at >=20 weeks of gestation.

160 We are enrolling 800 pregnant women at each of the 4 international research c

161 effective strategy to identify HBV-infected pregnant women at risk of perinatal transmission in coun

162 s hinders the identification of HBV-infected pregnant women at risk of perinatal transmission.

163 ion, whereas the ultimate beneficiaries were pregnant women attending ANC.

164 .IMPORTANCE Although Zika virus infection of pregnant women can result in congenital Zika syndrome, t

165 oV-2 infection causes more severe disease in pregnant women compared to age-matched non-pregnant wome

166 RSV F protein nanoparticle vaccination in pregnant women did not meet the prespecified success cri

167 We analyzed data from 7553 HIV-negative pregnant women enrolled in a multivitamin trial at 12-27

168 udy, we collected participant-level data for pregnant women enrolled in the SUSTAIN and REFINE studie

169 ed in 2006 to evaluate perinatal outcomes in pregnant women exposed to omalizumab and their infants.

170 sed risk of major congenital anomalies among pregnant women exposed to omalizumab compared with a dis

171 Between 2007 and 2011, 948 pregnant women from Mexico City were recruited as part o

172 Data for 92,743 pregnant women from the Japan Environment and Children's

173 Pregnant women from Uganda and South Africa were randomi

174 Pregnant women had the highest VDD prevalence at 6.7% +/

175 Cohort and case-controlled studies of pregnant women have demonstrated periodontal disease as

176 al (Ctrough) was reduced by 77%, with 85% of pregnant women having a Ctrough below the effective conc

177 s inferred using tests administered to 1,746 pregnant women hospitalized for delivery between March 2

178 were analyzed from retrospective cohorts of pregnant women hospitalized with ARFI who had testing fo

179 y maternity service in London (UK), in which pregnant women identified at increased risk of PTB were

180 Inclusion of pregnant women in COVID-19 clinical trials would allow e

181 attention to the need and urgency to engage pregnant women in COVID-19 treatment trials now in order

182 randomized intervention trial enrolling 800 pregnant women in each of four countries (i.e., Peru, Gu

183 ticipant-level data from 1617 HIV-uninfected pregnant women in Kenya (one trial; n=806) and Uganda (t

184 evere pre-eclampsia in the PreCARE cohort of pregnant women in Paris (n = 9,579).

185 d, open-label trial, DolPHIN-2, we recruited pregnant women in South Africa and Uganda aged at least

186 ted from August 2013 to May 2016 among 3,967 pregnant women in the Tongji Maternal and Child Health C

187 out temporal trends of phthalate exposure in pregnant women in the United States.

188 been assessed in many risk groups, including pregnant women in whom influenza may manifest differentl

189 From 2014 to 2018, we enrolled 179 pregnant women into 4 groups: "HLHS/TGA" fetuses with hy

190 violence may indirectly affect health among pregnant women living in neighborhoods where it is endem

191 Data on the safety and efficacy of IPT in pregnant women living with HIV (PWLHIV) are mixed.

192 Between Feb 11, and June 6, 2013, 800 pregnant women living with HIV were enrolled and randoml

193 ransmission of HIV [eMTCT] and the health of pregnant women living with HIV) and repeat HIV testing (

194 erred or alternative integrase inhibitor for pregnant women living with HIV.

195 nogenicity than did a single-dose regimen in pregnant women living with HIV.

196 ring these campaigns with recommended doses, pregnant women might be inadvertently exposed.

197 ur data come from a case-control study of 90 pregnant women nested within the LIFECODES prospective b

198 h those from a disease-matched population of pregnant women not treated with omalizumab.

199 ertussis epidemiology among pregnant and non-pregnant women of childbearing age.

200 des and bisphenol A (mixture N1) detected in pregnant women of the SELMA cohort and associated with l

201 n nutritional recommendations, counseling of pregnant women on diet and physical activity recommendat

202 ementation in mildly-to-moderately deficient pregnant women on maternal and infant thyroid function a

203 Pool walking may improve renal function in pregnant women partly through the suppressed renin-angio

204 In a cohort of pregnant women patterns of allergic sensitization in adu

205 e SARS-CoV-2 test results among asymptomatic pregnant women presenting for labor and delivery at Yale

206 llular vesicles (sEVs) isolated from healthy pregnant women promote islet glucose-stimulated insulin

207 MoBa includes about 95,000 pregnant women recruited throughout Norway from 1999 to

208 he study period, 26.3% (95% CI 25.7-27.0) of pregnant women referred by criminal justice agencies rec

209 examine trends in medications for OUD among pregnant women referred to treatment by criminal justice

210 udies for COVID-19, the proportion excluding pregnant women remains consistent.

211 Uptake of influenza vaccine among pregnant women remains low.

212 A total of 397 pregnant women suffered from severe maternal outcomes am

213 natal glucocorticoid therapy administered to pregnant women threatened with preterm birth is also dis

214 veloped Markov models of HIV and syphilis in pregnant women to estimate costs and infant health outco

215 activity programs with optimal intensity for pregnant women to prevent and treat their psychological

216 dertook a prospective study enrolling normal pregnant women undergoing elective caesarean section.

217 Universal HCV rescreening among pregnant women was cost-effective (ICER $6,000/QALY) and

218 In conclusion, unvaccinated pregnant women were clustered geographically and by key

219 We investigated whether unvaccinated pregnant women were clustered geographically and determi

220 Pregnant women were eligible if they were aged 18-38 yea

221 Results A total of 2952 pregnant women were evaluated.

222 Placentas from 134 pregnant women were examined after delivery for patholog

223 A total of 4631 pregnant women were recruited (IG, n = 2565; and CG, n =

224 Pregnant women were screened for Chagas disease by rapid

225 cal characteristics of COVID-19 pneumonia in pregnant women were similar to those reported for non-pr

226 All pregnant women who attended their first antenatal visit

227 An uncommon but important complication in pregnant women who become acutely infected with Brucella

228 od for HIV acquisition in African women, and pregnant women who become acutely infected with HIV acco

229 study in a referral center by collecting all pregnant women who diagnosed as pre-eclampsia and delive

230 ma collected longitudinally from children of pregnant women who had been followed closely through pre

231 data exist about the role of betatrophin in pregnant women with a history of Roux-En-Y gastric bypas

232 There were 6390 pregnant women with acute cholecystitis: 38.2% underwent

233 1196 pregnant women with AMSB underwent a 21-24 week "placent

234 an Heart Association recommends providers of pregnant women with CHD assess cardiac health and discus

235 Contemporary outcomes of pregnant women with cirrhosis and their infants, as well

236 nary teams are needed to coordinate care for pregnant women with cirrhosis during pregnancy and postp

237 Limited data are available for pregnant women with COVID-19 pneumonia.

238 ing the potential for severe morbidity among pregnant women with COVID-19.FUNDINGBeatrice Kleinberg N

239 ncidence of serious cardiac events (SCEs) in pregnant women with heart disease, whether they were pre

240 Our findings suggest that among HIV-negative pregnant women with high uptake of long-lasting insectic

241 (68 IIV3 and 77 placebo recipients) and 140 pregnant women with HIV infection (72 IIV3 and 68 placeb

242 Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective,

243 Pregnant women with inflammatory bowel disease (IBD) may

244 Results from 15 pregnant women with ITP (pregnancies, n = 17; neonates,

245 In pregnant women with laboratory-confirmed ZVD, brain or e

246 c index (GI) diet plus physical activity) in pregnant women with obesity (294 contol, 263 interventio

247 Criminal justice involvement is common among pregnant women with opioid use disorder (OUD).

248 Pregnant women with OUD referred by criminal justice age

249 n March 21 to June 16, 2020 for hospitalized pregnant women with PCR-confirmed SARS-CoV-2 infection a

250 t outcome were analyzed in a database of 304 pregnant women with primary infection.

251 In the cohort of pregnant women with RYGB and exaggerated risk of postpra

252 r disease, limiting the options available to pregnant women with severe COVID-19 to compassionate use

253 lts emphasize the need to treat or prophylax pregnant women with suspected plague with highly effecti

254 d cardiovascular readmissions in a cohort of pregnant women with underlying cardiovascular disease (C

255 A total of 11,944 pregnant women with ZVD were reported in Colombia, with

256 Of 18,117 pregnant women with ZVD, the presence of Zika virus was

257 han historical data from the same setting in pregnant women without HIV.

258 Overall, 44 clusters (69 330 pregnant women) were randomly assigned to intervention (

259 Among 958 980 pregnant women, 10% received opioids only, 6% psychotrop

260 In order to better characterize GDM in pregnant women, 100 blood plasma samples (50 GDM and 50

261 s (ARFI) and influenza-associated ARFI among pregnant women, administrative and electronic health rec

262 Consenting pregnant women, aged 12-49 years, were recruited in thei

263 We recruited non-pregnant women, aged 25 years or older, who were eligibl

264 ly, in 31,841 children aged 1 to <18 y, 1262 pregnant women, and 7170 nonpregnant women aged 18-49 y.

265 representative sample of Colombian children, pregnant women, and adult nonpregnant women.

266 a inactivated vaccine (IIV3) immunization in pregnant women, and association with protection against

267 cause of bacteremia and sepsis in newborns, pregnant women, and immunocompromised patients.

268 artum in a cohort of obese and normal-weight pregnant women, as well as in women with a history of RY

269 Healthy pregnant women, at 28 weeks 0 days through 36 weeks 0 da

270 In a subgroup of 1850 pregnant women, more than 90% of women who were reported

271 pediatric populations (age < 16 years old), pregnant women, noncritically ill patients, very specifi

272 Among pregnant women, VDD was positively related to education.

273 In comparison to normal-weight and obese pregnant women, women with a history of RYGB operation a

274 in treatment for COVID-19, 27 (77%) excluded pregnant women.

275 onal studies that reported adverse events in pregnant women.

276 es, of which 538 (75%) specifically excluded pregnant women.

277 en, these relationships are underexplored in pregnant women.

278 of developing treatment recommendations for pregnant women.

279 and economic impact of seasonal influenza on pregnant women.

280 ected more than 10 million people, including pregnant women.

281 es, as changes of breast volume vary between pregnant women.

282 to further define pertussis epidemiology in pregnant women.

283 n pregnant women compared to age-matched non-pregnant women.

284 cy outcomes were evaluated for a subgroup of pregnant women.

285 ing, supporting recommendations to vaccinate pregnant women.

286 tabolome of 784 weekly blood samples from 30 pregnant women.

287 sters with a high prevalence of unvaccinated pregnant women.

288 effect of pool walking on renal function in pregnant women.

289 eventing and managing bacterial infection in pregnant women.

290 nt, of which 124 (80%) specifically excluded pregnant women.

291 posures in Mexican populations, particularly pregnant women.

292 forts on preventing inadvertent treatment of pregnant women.

293 f disease are similar among pregnant and non-pregnant women.

294 sion and described 160 cases of plague among pregnant women.

295 adverse events after ivermectin exposure in pregnant women.

296 place despite experience with these drugs in pregnant women.

297 uch correlation was seen in the normotensive pregnant women.

298 000 among pregnant and 7.3/100,000 among non-pregnant women.

299 counts of >=10(5) CFU/ml in women, including pregnant women; a single voided urine specimen with one

300 eloid cells were elevated in the placenta of pregnant ZIKV-infected Rag1(-/-) mice treated with an an